Skip to main content
NIH funding notice PAR-22-110

NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U24 Clinical Trial Not Allowed)

Closed on September 25, 2024.

Posted
February 3, 2022
Close date
September 25, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $31,387,005 in first-year total cost, median $15,693,503.

Most frequent study sections

  1. Special Emphasis Panel[ZAG1 ZIJ-G (M3)]1
  2. Special Emphasis Panel[ZAG1 ZIJ-S (J1)]1

Most frequent institutions

  1. SAGE BIONETWORKS1
  2. UNIVERSITY OF SOUTHERN CALIFORNIA1
Competing awards under PAR-22-110 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024The AD Knowledge Portal Data Coordination Center2U24AG061340-06HEATH, LAURA MICHELLEVARMA, SUSHEELSAGE BIONETWORKS, WA$3,261,591ZAG1
2023Alzheimer's Clinical Trials Consortium (ACTC)2U24AG057437-06AISEN, PAUL S.PETERSEN, RONALD CSPERLING, REISA A.UNIVERSITY OF SOUTHERN CALIFORNIA, CA$28,125,414ZAG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.